Skip to content
Sexuality – Lifestyle
Author:
Immuneering Corporation
Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO
June 1, 2026
←
Previous Page
1
2
3